Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Snooze Control: Sleep Duration & Glucose Metabolism
Snooze Control: The Effect of Sleep Deprivation on Glucose Metabolism
Status: Enrolling
Updated:  10/20/2015
Public Health Research Center University of South Carolina
mi
from
Columbia, SC
Snooze Control: Sleep Duration & Glucose Metabolism
Snooze Control: The Effect of Sleep Deprivation on Glucose Metabolism
Status: Enrolling
Updated: 10/20/2015
Public Health Research Center University of South Carolina
mi
from
Columbia, SC
Click here to add this to my saved trials
G-Pen™ for Hypoglycemia Rescue in T1D
G-Pen™ (Glucagon Injection) for Induced Hypoglycemia Rescue in Adult Patients With T1D
Status: Enrolling
Updated:  10/25/2015
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
G-Pen™ for Hypoglycemia Rescue in T1D
G-Pen™ (Glucagon Injection) for Induced Hypoglycemia Rescue in Adult Patients With T1D
Status: Enrolling
Updated: 10/25/2015
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Click here to add this to my saved trials
Exercise Intensity, Metabolic Rate and Insulin Sensitivity
Status: Enrolling
Updated:  10/26/2015
UAB
mi
from
Birmingham, AL
Exercise Intensity, Metabolic Rate and Insulin Sensitivity
Status: Enrolling
Updated: 10/26/2015
UAB
mi
from
Birmingham, AL
Click here to add this to my saved trials
Laparoscopic Adjustable Gastric Banding (LAGB) as a Treatment for Morbid Obesity in Adolescents
LAGB Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents
Status: Enrolling
Updated:  10/27/2015
Morgan Stanley Children's Hospital of NY Presbyterian
mi
from
New York, NY
Laparoscopic Adjustable Gastric Banding (LAGB) as a Treatment for Morbid Obesity in Adolescents
LAGB Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents
Status: Enrolling
Updated: 10/27/2015
Morgan Stanley Children's Hospital of NY Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated:  10/27/2015
Clinical Research Facility
mi
from
Houston, TX
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated: 10/27/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated:  10/27/2015
Investigational Site Number 203002
mi
from
Olomouc,
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated: 10/27/2015
Investigational Site Number 203002
mi
from
Olomouc,
Click here to add this to my saved trials
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs
Status: Enrolling
Updated:  10/28/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs
Status: Enrolling
Updated: 10/28/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs
Status: Enrolling
Updated:  10/28/2015
Campus Charité Mitte
mi
from
Berlin,
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs
Status: Enrolling
Updated: 10/28/2015
Campus Charité Mitte
mi
from
Berlin,
Click here to add this to my saved trials
Health Protection & Promotion for Oregon Correctional Officers
Health Protection & Promotion for Oregon Correctional Officers
Status: Enrolling
Updated:  10/28/2015
Oregon Health and Science University
mi
from
Portland, OR
Health Protection & Promotion for Oregon Correctional Officers
Health Protection & Promotion for Oregon Correctional Officers
Status: Enrolling
Updated: 10/28/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Single Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Doses of Long Acting HGH Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
Status: Enrolling
Updated:  10/28/2015
Wcct Global, Llc
mi
from
Cypress, CA
Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Single Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Doses of Long Acting HGH Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
Status: Enrolling
Updated: 10/28/2015
Wcct Global, Llc
mi
from
Cypress, CA
Click here to add this to my saved trials
Wellbutrin XL for Dysthymic Disorder
Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL
Status: Enrolling
Updated:  10/29/2015
Mood Disorders Research Program, St. Luke's-Roosevelt Hospital Center
mi
from
New York, NY
Wellbutrin XL for Dysthymic Disorder
Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL
Status: Enrolling
Updated: 10/29/2015
Mood Disorders Research Program, St. Luke's-Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity
Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity
Status: Enrolling
Updated:  11/3/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity
Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity
Status: Enrolling
Updated: 11/3/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effects of Milk Protein Concentrate on Overall Health During Weight Loss in Overweight/Obese Adults
Effects of Milk Protein Concentrate on Blood Pressure, Inflammation, Muscle Health During Weight Loss in Overweight/Obese Adults
Status: Enrolling
Updated:  11/3/2015
Purdue University - Stone Hall 700 W State St
mi
from
W Lafayette, IN
Effects of Milk Protein Concentrate on Overall Health During Weight Loss in Overweight/Obese Adults
Effects of Milk Protein Concentrate on Blood Pressure, Inflammation, Muscle Health During Weight Loss in Overweight/Obese Adults
Status: Enrolling
Updated: 11/3/2015
Purdue University - Stone Hall 700 W State St
mi
from
W Lafayette, IN
Click here to add this to my saved trials
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake
Status: Enrolling
Updated:  11/4/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake
Status: Enrolling
Updated: 11/4/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Value of 25 mcg Cortrosyn Stimulation Test
The Value of 25 mcg Cortrosyn Stimulation Test to Assess Adult HPA Axis
Status: Enrolling
Updated:  11/4/2015
Cleveland Clinic Department of Endocrinology
mi
from
Cleveland, OH
Value of 25 mcg Cortrosyn Stimulation Test
The Value of 25 mcg Cortrosyn Stimulation Test to Assess Adult HPA Axis
Status: Enrolling
Updated: 11/4/2015
Cleveland Clinic Department of Endocrinology
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
San Francisco, CA
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Louisville, KY
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Kansas City, MO
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated:  11/5/2015
mi
from
Leuven,
Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease
An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Status: Enrolling
Updated: 11/5/2015
mi
from
Leuven,
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Cedars-Sinai Medical Center, Pituitary Center
mi
from
Los Angeles, CA
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Cedars-Sinai Medical Center, Pituitary Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
University of California at Los Angeles Division of Endocrinology
mi
from
Los Angeles, CA
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
University of California at Los Angeles Division of Endocrinology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Stanford University Medical Center Stanford Cancer Center (3)
mi
from
Stanford, CA
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Stanford University Medical Center Stanford Cancer Center (3)
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
University of Florida SC
mi
from
Gainesville, FL
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
University of Florida SC
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Johns Hopkins University School of Medicine Dept.ofJohnsHopkinsUniv.
mi
from
Baltimore, MD
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Johns Hopkins University School of Medicine Dept.ofJohnsHopkinsUniv.
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
University of Michigan Comprehensive Cancer Center Deptof Endocrinology&Diabetes
mi
from
Ann Arbor, MI
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
University of Michigan Comprehensive Cancer Center Deptof Endocrinology&Diabetes
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Columbia University Medical Center- New York Presbyterian Dept. of CU Collegeof Phys&Sur
mi
from
New York, NY
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Columbia University Medical Center- New York Presbyterian Dept. of CU Collegeof Phys&Sur
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Northport VA Medical Center CSOM230C2305
mi
from
Northport, NY
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Northport VA Medical Center CSOM230C2305
mi
from
Northport, NY
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Oregon Health & Sciences University DeptofOregonHealth&Sciences(3)
mi
from
Portland, OR
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Oregon Health & Sciences University DeptofOregonHealth&Sciences(3)
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Allegheny Endocrinology Associates
mi
from
Pittsburgh, PA
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Allegheny Endocrinology Associates
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
University of Texas Southwestern Medical Center Danziger Research Bldg.
mi
from
Dallas, TX
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
University of Texas Southwestern Medical Center Danziger Research Bldg.
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
University of Texas/MD Anderson Cancer Center Regulatory -12
mi
from
Houston, TX
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
University of Texas/MD Anderson Cancer Center Regulatory -12
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Baylor College of Medicine
mi
from
Houston, TX
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Swedish Medical Center Dept.ofSeattle Neuroscience(2)
mi
from
Seattle, WA
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Swedish Medical Center Dept.ofSeattle Neuroscience(2)
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated:  11/7/2015
Novartis Investigative Site
mi
from
Capital Federal,
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Status: Enrolling
Updated: 11/7/2015
Novartis Investigative Site
mi
from
Capital Federal,
Click here to add this to my saved trials
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Status: Enrolling
Updated:  11/10/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Status: Enrolling
Updated: 11/10/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
Advance Medical Research LLC
mi
from
Lakewood, CA
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
Advance Medical Research LLC
mi
from
Lakewood, CA
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
Massachusetts General Hospital
mi
from
Boston, MA
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
Michigan Bone and Mineral Clinic, PC
mi
from
Detroit, MI
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
Michigan Bone and Mineral Clinic, PC
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
University Physicians Group
mi
from
Staten Island, NY
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
University Physicians Group
mi
from
Staten Island, NY
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
Physician East PA
mi
from
Greenville, NC
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
Physician East PA
mi
from
Greenville, NC
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
The Vancouver Clinic
mi
from
Vancouver, WA
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
The Vancouver Clinic
mi
from
Vancouver, WA
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
Indiana University School of Medicine
mi
from
Indianapolis, IN
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
Columbia University Medical Center
mi
from
New York, NY
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
University of Cincinnati Bone Health and Osteoporosis Center
mi
from
Cincinnati, OH
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
University of Cincinnati Bone Health and Osteoporosis Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated:  11/10/2015
Cetero Research DGD Research Inc.
mi
from
San Antonio, TX
Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Status: Enrolling
Updated: 11/10/2015
Cetero Research DGD Research Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Status: Enrolling
Updated:  11/10/2015
UMASS Memorial Health Care
mi
from
Worcester, MA
Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Status: Enrolling
Updated: 11/10/2015
UMASS Memorial Health Care
mi
from
Worcester, MA
Click here to add this to my saved trials
A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Open-label Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous NPSP795 in Autosomal Dominant Hypocalcemia Due to Mutations in the Calcium-sensing Receptor Gene: A Drug Repurposing Study
Status: Enrolling
Updated:  11/10/2015
National Institute of Health (NIH)
mi
from
Bethesda, MD
A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Open-label Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous NPSP795 in Autosomal Dominant Hypocalcemia Due to Mutations in the Calcium-sensing Receptor Gene: A Drug Repurposing Study
Status: Enrolling
Updated: 11/10/2015
National Institute of Health (NIH)
mi
from
Bethesda, MD
Click here to add this to my saved trials